Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol-Reference-Cited by-同舟云学术

Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol

Published:2020-07-17 Issue:6 Volume:108 Page:1213-1223
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Ghonem Nisanne S.¹,Auclair Adam M.¹^ORCID,Hemme Christopher L.²^ORCID,Gallucci Gina M.¹,Rosa Rodriguez Randolph³,Boyer James L.³,Assis David N.³

Affiliation:

1. Department of Biomedical and Pharmaceutical Sciences College of Pharmacy University of Rhode Island Kingston Rhode Island USA

2. RI‐INBRE Bioinformatics Core University of Rhode Island Kingston Rhode Island USA

3. Liver Center Yale University School of Medicine New Haven Connecticut USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1930

Reference31 articles.

1. Bile formation and secretion;Boyer J.L.;Compr. Physiol.,2013

2. Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response

3. Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment

4. Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection

5. Fibrates and cholestasis

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases;Cells;2024-08-01

2. Efficacy and safety of peroxisome proliferator-activated receptor agonists for the treatment of primary biliary cholangitis: a meta-analysis of randomized controlled trials;Frontiers in Pharmacology;2024-07-22

3. PPAR agonists in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials;2024-05-14

4. Navigating the liver landscape: upcoming pharmacotherapies for primary sclerosing cholangitis;Expert Opinion on Pharmacotherapy;2024-05-02

5. Novel preclinical developments of the primary sclerosing cholangitis treatment landscape;Expert Opinion on Investigational Drugs;2024-03-18